Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis (Q38383470)

2 September 2017

Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis (English)

1 reference

2 September 2017

0 references

Rong Qiu

1

1 reference

2 September 2017

Dainius Balis

2

1 reference

2 September 2017

John Xie

3

1 reference

2 September 2017

Michael J Davies

4

1 reference

2 September 2017

Mehul Desai

5

1 reference

2 September 2017

Gary Meininger

6

1 reference

2 September 2017

language of work or name

English

0 references

publication date

15 December 2016

1 reference

Current Medical Research and Opinion

2 September 2017

1 reference

2 September 2017

33

1 reference

2 September 2017

553-562

1 reference

2 September 2017

3

1 reference

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

2 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Urinary tract infections in patients with diabetes treated with dapagliflozin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1271780

10.1080/03007995.2016.1271780

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference